Pathogen genomics employs advanced sequencing to analyze the DNA and RNA of pathogens, enabling scientists to create vaccines that target essential parts of their structure. By identifying genes involved in virulence, immune evasion, or resistance, researchers can design vaccines that are highly specific, minimizing unwanted effects. This genomic information allows for targeted vaccines that not only elicit a stronger immune response but also improve safety and efficacy. Additionally, pathogen genomics aids in tracking mutations and emerging variants, a crucial feature for diseases like influenza or COVID-19, where frequent genetic changes can impact vaccine efficacy. The ability to monitor these changes in real time ensures vaccines remain effective, helping public health agencies respond swiftly to new threats and ultimately aiding in the containment and eradication of infectious diseases.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey